Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01695733 · ClinicalTrials.gov registry record · Phase 1
Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01695733 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 21 participants.
The verdict
NCT01695733, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This clinical trial studies the best time to administer the influenza vaccine to patients with non-hematologic malignancies receiving chemotherapy. Giving the vaccine at different times relative to chemotherapy may affect how well it works to help the body build an immune response and prevent influenza in these patients.
Interventions
- BIOLOGICAL trivalent influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01695733
The ClinicalTrials.gov registry entry for NCT01695733 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which trivalent influenza vaccine is the first listed.
NCT01695733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01695733 about?
NCT01695733 is a clinical study titled "Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy". This clinical trial studies the best time to administer the influenza vaccine to patients with non-hematologic malignancies receiving chemotherapy. Giving the vaccine at different times relative to chemotherapy may affect how well it works to help the body build an immune response and prevent influe...
What is the current status of trial NCT01695733?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2011-09. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01695733?
The interventions under investigation include: trivalent influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01695733?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.